Open AccessLow High-Density Lipoprotein and Risk of Myocardial Infarction
Author(s) -
Alfredo Ramı́rez,
Pengcheng Hu
Publication year - 2015
Publication title -
clinical medicine insights cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.634
H-Index - 21
ISSN - 1179-5468
DOI - 10.4137/cmc.s26624
Subject(s) - myocardial infarction , evolocumab , medicine , cardiology , alirocumab , lipoprotein , cholesterol , apolipoprotein a1
Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom